-+ 0.00%
-+ 0.00%
-+ 0.00%

Kempen Upgrades UCB to Buy Rating, Boosts PT

MT Newswires·07/30/2026 08:30:28
Listen to the news
08:30 AM EDT, 07/30/2026 (MT Newswires) -- Kempen on Thursday upgraded Belgian biopharmaceutical company UCB (UCB.BR) to buy from neutral and increased its price target to 340 euros from 245 euros. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)